Interpace Biosciences, Inc. (IDXG)
Market Cap | 5.34M |
Revenue (ttm) | 40.66M |
Net Income (ttm) | 919,000 |
Shares Out | 4.38M |
EPS (ttm) | 0.21 |
PE Ratio | 5.79 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 622 |
Open | 1.220 |
Previous Close | n/a |
Day's Range | n/a |
52-Week Range | 1.030 - 1.260 |
Beta | 0.67 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 10, 2021 |
About IDXG
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis and prognosis of pancreatic cancer; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expre... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/o/5/press2-2422484.jpg)
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2024 a...
![](https://cdn.snapi.dev/images/v1/l/y/press2-2312938.jpg)
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fourth quarter and full year endin...
![](https://cdn.snapi.dev/images/v1/g/k/press19-2147901.jpg)
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2...
![](https://cdn.snapi.dev/images/v1/r/z/press3-2015204.jpg)
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2023 ...
![](https://cdn.snapi.dev/images/v1/6/6/press9-1964841.jpg)
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement
PARSIPPANY, NJ, July 10, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced preliminary business results for the second quarter ending Ju...
![](https://cdn.snapi.dev/images/v1/v/o/press12-1921604.jpg)
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023
PARSIPPANY, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Centers for Medicare & Medicaid Services (CMS) issue...
![](https://cdn.snapi.dev/images/v1/h/g/press4-1888205.jpg)
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results
PARSIPPANY, NJ, May 12, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2023 a...
![](https://cdn.snapi.dev/images/v1/c/a/press4-1814127.jpg)
Interpace Biosciences Announces Full Year and Fourth Quarter 2022 Financial and Business Results
PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter end...
![](https://cdn.snapi.dev/images/v1/x/a/press12-1636336.jpg)
Interpace Biosciences Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern
PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2...
![](https://cdn.snapi.dev/images/v1/p/g/press19-1592470.jpg)
Interpace Biosciences Announces New Real-world Data; Presented at the American Thyroid Association 2022 Annual Meeting
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mole...
![](https://cdn.snapi.dev/images/v1/z/k/press11-1529139.jpg)
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
PARSIPPANY, NJ, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mol...
![](https://cdn.snapi.dev/images/v1/z/j/press16-1527070.jpg)
Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc.
PARSIPPANY, NJ, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”), a leader in enabling personalized medicine, has announced the closing of a d...
![](https://cdn.snapi.dev/images/v1/p/y/press5-1376771.jpg)
Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the first quarter ended March 31, 2022 a...
![](https://cdn.snapi.dev/images/v1/1/f/press10-1302273.jpg)
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal year and fourth quarter end...
![](https://cdn.snapi.dev/images/v1/x/g/press12-1208111.jpg)
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests
PARSIPPANY, NJ, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace” or the “Company”) a leader in enabling personalized medicine, announced today that it was termi...
![](https://cdn.snapi.dev/images/v1/v/x/press12-1205608.jpg)
Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director
PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX: IDXG) (“Interpace”) a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal,...
![](https://cdn.snapi.dev/images/v1/n/c/press15-1183581.jpg)
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering
PARSIPPANY, NJ, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it commenced its previously announced fully back-stopped...
![](https://cdn.snapi.dev/images/v1/f/d/press13-1169883.jpg)
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering
Proceeds to be used to fund the organic growth and prospective product line acquisitions
![](https://cdn.snapi.dev/images/v1/g/0/press5-1083121.jpg)
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans
PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new ...
![](https://cdn.snapi.dev/images/v1/t/o/press7-1073065.jpg)
Interpace Biosciences Announces U.S. PTO Issuance of Patent No. 11,143,657 Titled: Topographic Genotyping for Determining the Diagnosis, Malignant Potential, and Biologic Behavior of Pancreatic Cysts and Related Conditions
PARSIPPANY, NJ, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mole...
![](https://cdn.snapi.dev/images/v1/j/l/press13-1060320.jpg)
Interpace Diagnostics Announces US Patent Approval for Patent Application No. 11,118, 231 B2 Titled: microRNAs as Biomarkers for Distinguishing Benign from Malignant Thyroid Neoplasms
PARSIPPANY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant mole...
![](https://cdn.snapi.dev/images/v1/i/d/press6-1051181.jpg)
Interpace Biosciences Announces New $7.5 Million Credit Facility with Comerica Bank
PARSIPPANY, NJ, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a new ...
![](https://cdn.snapi.dev/images/v1/v/d/press2-826526.jpg)
Interpace Pharma Solutions Announces New Capability in Spatial Biology/Precision Oncology Services
Parsippany, NJ, May 17, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that it will offer...
![](https://cdn.snapi.dev/images/v1/k/m/press4-818350.jpg)
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 ...
![](https://cdn.snapi.dev/images/v1/x/m/press20-771752.jpg)
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally ...